Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  2. Drug

    Rhus Glabra Pollen

    go.drugbank.com/drugs/DB13895
    Approved

    Rhus Glabra Pollen pollen is the pollen of the Rhus Glabra Pollen plant. The pollen is mainly used in allergenic testing.

  3. Drug

    Codrituzumab

    go.drugbank.com/drugs/DB14843
    Investigational

    Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).

  4. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

  5. Drug

    Sepetaprost

    go.drugbank.com/drugs/DB12043
    Investigational

    Sepetaprost has been used in trials studying the treatment of Open Angle-glaucoma, Ocular Hypertension, and Mild Open Angle-glaucoma (OAG).

  6. Drug

    BMS-599626

    go.drugbank.com/drugs/DB12318
    Investigational

    BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.

  7. Drug

    Vesencumab

    go.drugbank.com/drugs/DB15428
    Investigational

    Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).

  8. Drug

    Rocbrutinib

    go.drugbank.com/drugs/DB19445
    Investigational

    Rocbrutinib is under investigation in clinical trial NCT05716087 (A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma).

  9. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. … Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer.

  10. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.